Restricted Access

Before you enter

All products are sold strictly for in-vitro laboratory research — not for human consumption, therapeutic, or veterinary use.

Your confirmation is saved for 7 days. You will only be asked to confirm once per week.
By entering you accept full responsibility for compliance with all applicable laws.

For research use only  ·  Not for human or animal consumption
Home/Products/Ipamorelin
Ipamorelin research vial Third-party tested
GH Secretagogue Peptide

Ipamorelin

NNC 26-0161
CAS 170851-70-4 Aib-His-D-2Nal-D-Phe-Lys-NH2

A selective pentapeptide ghrelin-receptor (GHSR-1a) agonist, studied for growth hormone release in research models.

$40.00$8.00 / mg
Strength

Availability: 5 in stock

Fast U.S. shippingFree on orders over $200
Third-party testedIndependent lab, every batch
Purity documentedHPLC + mass spec
Secure checkoutVenmo · Cash App · Zelle
01Research snapshot

Ipamorelin, by the numbers.

Structural and laboratory facts that define this compound. For laboratory research use only.

0
Amino acid residues

Synthetic pentapeptide

0
Molecular weight

g/mol · C38H49N9O5

0
Receptor target

GHSR-1a (ghrelin receptor)

0
First described

Novo Nordisk research

02Molecular structure

The Ipamorelin molecule

A schematic atomic representation shown next to the compound's molecular data. The figure is illustrative, not a measured conformation.

CHNOS
Molecular formula
C38H49N9O5
Mol. weight711.9 g/mol
Sequence length5 residues
CAS170851-70-4
Physical formLyophilized powder
Purity99%+ HPLC
Use classResearch only
AibHisD-2NalD-PheLys-NH2
03Mechanism of action

How it is studied.

The first truly selective GH secretagogue — GH release without cortisol, ACTH, or prolactin elevation

01
GHSR-1a Agonist Ghrelin Receptor Activation

Ipamorelin selectively binds Growth Hormone Secretagogue Receptor 1a (GHSR-1a) on anterior pituitary somatotrophs, triggering GH release in a dose-dependent manner. It acts via the same receptor as ghrelin but with greater selectivity and without the appetite-stimulating off-target effects.

  • Selective GHSR-1a (ghrelin receptor) agonism
  • Dose-dependent GH release (ED50: 80 nmol/kg)
  • No desensitization with repeated administration
02
Selectivity No Cortisol or Prolactin Elevation

Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly elevate ACTH, cortisol, or prolactin at doses that produce substantial GH release. This was demonstrated in dose-escalation studies and marks ipamorelin as the first pentapeptide GH secretagogue with this selectivity profile.

  • No ACTH or cortisol elevation (unlike GHRP-6)
  • No significant prolactin elevation
  • Clean pituitary selectivity
03
Pulsatile GH Physiologic GH Secretion Pattern

Ipamorelin stimulates GH release in discrete, pulsatile bursts similar to endogenous GH secretion physiology. This pulsatile pattern is considered more physiologically appropriate than continuous GH elevation, and is preserved across multiple administration cycles.

  • Preserves pulsatile GH secretion pattern
  • Peak GH at approximately 40 minutes post-dose
  • Additive effect when combined with GHRH analogs

Research pathway map

The primary pathways Ipamorelin is investigated against in laboratory models.

IpamorelinTARGETS01GHSR-1a Agonist02Selectivity03Pulsatile GH
Illustrative schematic based on published in-vitro and preclinical observations. Research use only.
04Specifications

Compound details.

Chemical nameIpamorelin (NNC 26-0161)
SynonymsNNC 26-0161
SequenceAib-His-D-2Nal-D-Phe-Lys-NH2
FormulaC38H49N9O5
Molecular weight711.9 g/mol
CAS number170851-70-4
FormLyophilized powder
DocumentationThird-party COA, per batch

Storage & handling

Supplied as a lyophilized powder. Store the sealed vial refrigerated at 2–8°C, protected from light and moisture; −20°C for long-term storage. Keep reconstituted material refrigerated.

FOR RESEARCH USE ONLYNot for human or animal consumption. Intended strictly for qualified researchers performing in-vitro or analytical laboratory work. No medical, diagnostic or therapeutic claims are made.
Eur J Endocrinol · 1998Ipamorelin, the first selective growth hormone secretagogue

Original pharmacological characterization.

Raun K et al., 1998 · PubMed ↗
Growth Horm IGF Res · 1999Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Rodent model study.

Johansen PB et al., 1999 · PubMed ↗
Pharm Res · 1999Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Pharmacokinetic modeling study.

Gobburu JV et al., 1999 · PubMed ↗
0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Scroll to Top